Key terms for the assessment of the safety of vaccines in pregnancy: Results of a global consultative process to initiate harmonization of adverse event definitions

Vaccine

Volumn 33, Issue 47, 2015, Pages 6441-6452

  Munoz, Flor M ^a   Eckert, Linda O ^b   Katz, Mark A ^c   Lambach, Philipp ^d   Ortiz, Justin R ^d   Bauwens, Jorgen ^e   Bonhoeffer, Jan ^e,f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c World Health Organization ^*  (Israel)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e Brighton Collaboration Foundation   (Switzerland)

^f UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

AEFI; Brighton; Maternal immunization; Pregnancy; Safety; Vaccines

Indexed keywords

INFLUENZA VACCINE; VACCINE; YELLOW FEVER VACCINE;

ADVERSE OUTCOME; ARTICLE; CONSENSUS; DRUG SAFETY; FEMALE; HEALTH PROGRAM; HUMAN; IMMUNIZATION; INJECTION SITE REACTION; PATIENT MONITORING; PREDICTIVE VALUE; PREGNANCY; PRIORITY JOURNAL; SWITZERLAND; SYSTEMATIC REVIEW; ADVERSE DRUG REACTION; ADVERSE EFFECTS; DISEASE TRANSMISSION; HEALTH; NOMENCLATURE; POSTMARKETING SURVEILLANCE; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; STANDARDS; WORLD HEALTH ORGANIZATION;

DISEASE TRANSMISSION, INFECTIOUS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GLOBAL HEALTH; HUMANS; IMMUNIZATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRODUCT SURVEILLANCE, POSTMARKETING; TERMINOLOGY AS TOPIC; VACCINES; WORLD HEALTH ORGANIZATION;

EID: 84947996250     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.07.112     Document Type: Article

References (65)

1. Lindsey B., Kampmann B., Jones C. Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants. Curr Opin Infect Dis 2013, 26:248-253.
2. WHO. Maternal and neonatal tetanus elimination (MNTE) initiative.WHO; 2014. Available from: http://www.who.int/immunizationmonitoring/diseases/MNTEinitiative/en/index.html, (accessed July, 2014).
3. Centers for Disease Control and Prevention Prevention and control of influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2010, 59:1-62.
4. Public Health England Influenza. The green book 2012, Available at: 〈https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224775/JCVI-statement-on-the-annual-influenza-vaccination-programme-25-July-2012.pdf〉 (chapter 19).
5. Advisory Committee on Immunization Practices (ACIP) Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women-ACIP 2012. MMWR 2013, 62(Feb (7)):131-135.
6. Amirthalingam G., Andrews N., Campbell H., Ribeiro S., Kara E., Donegan K., et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 2014, 384(9953):1521-1528. Oct 25.
7. National Institutes of Health Clinical trials 2015, National Institutes of Health, Available at 〈http://www.clinicaltrials.org〉 (accessed March 21, 2015).
8. Bonhoeffer J., Kohl K., Chen R.T., Duclos P., Heijbel H., Heininger H., et al. Standardized case definitions of adverse events following immunization (AEFI). Vaccine 2004, 22:547-550. The Brighton Collaboration.
9. Brighton Collaboration Guidelines for Data collection in Maternal and Neonatal Vaccine Trials. 〈https://brightoncollaboration.org/public/what-we-do/setting-standards/guidelines.html〉.
10. Beigi R.H., Goldkind S.F., Jevaji I. Research on vaccines and antimicrobials during pregnancy: challenges and opportunities. Vaccine 2013, 31:4261-4263.
11. Munoz F.M., Sheffield J.S., Beigi R.H., et al. Research on vaccines during pregnancy: protocol design and assessment of safety. Vaccine 2013, 31:4274-4279.
12. Sheffield J.S., Munoz F.M., Beigi R.H., et al. Research on vaccines during pregnancy: reference values for vital signs and laboratory assessments. Vaccine 2013, 31:4264-4273.
13. Munoz F.M., Weisman L.E., Read J.S., Siberry G., Kotloff K., Friedman J., et al. Assessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy. Clin Infect Dis 2014, 59(S7):S415-S428.
14. Beigi R.H., Fortner K.B., Munoz F.M., Roberts J., Gordon J.L., Han H.H., et al. Maternal immunization: opportunities for scientific advancement. Clin Infect Dis 2014, 59(S7):S408-S414.
15. World Health Organization Weekly Epidemiological Record, Vaccines against influenza WHO position paper - November 2012, WER No. 47, 2012, 87, 461-476, Available at: 〈http://www.who.int/wer〉.
16. World Health Organization Meeting of the Strategic Advisory Group of experts on immunization, November 2013-conclusions and recommendations. Vaccination of pregnant and lactating women. Wkly Epidemiol Rec 2014, 89:1-20. Available at: 〈http://www.who.int/wer〉 (WER No. 1).
17. World Health Organization Revised guidance on the choice of pertussis vaccines: July. Wkly Epidemiol Rec 2014, 89(Jul (30)):337-340. (2014).
18. Zaman K., et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008, 359:1155-1164.
19. Madhi S.A., Cutland C.L., Kuwanda L., Weingberg A., Hugo A., Jones S., et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014, 371:918-931.
20. Fulton T.R., et al. A systematic review of adverse events following immunization during pregnancy and the newborn period. Vaccine 2015, 33:6453-6465.
21. WHO and Brighton Collaboration Consultative Meeting Report, available at: 〈http://www.who.int/immunization/research/meetings_workshops/brighton_keyterms_safety_pregnancy.pdf?ua=1〉.
22. World Health Organization (WHO) AE definitions. Wkly Epidemiol Rep 2014, 89(1):1-20. Available at: 〈www.who.org〉.
23. World Health Organization Global manual on surveillance of adverse events following immunization (AEFI). Draft 2.0 Feb, 2014.
24. Global Advisory Committee on Vaccine Safety The safety of immunization during pregnancy. Wkly Epidemiol Rep 2013, 88(July):301-312. (June 2013, no. 29).
25. World Health Organization, Department of Making Pregnancy Safer. Family and community health, WHO. 〈www.who.int/making_pregnancy_safer〉.
26. World Health Organization The global action report on preterm birth 2012, World Health Organization, Geneva, (March of Dimes, PMNCH, Save Children, WHO. Born too Soon). C.P. Howson, M.V. Kinney, J.E. Lawn (Eds.).
27. National Institutes of Health (NIH) Division of AIDS (DAIDS) Table for grading the severity of adult and pediatric adverse events (Version 1.0 Dec 2004, Clarification August 2009; and Version 2.0 Draft May 2013) 2014, Available at: 〈http://rsc.tech-res.com/document/safetyandpharmacovigilance/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf〉 (accessed 29 May 2014).
28. National Institutes of Health (NIH) Division of Microbiology and Infectious Diseases (DMID) Pediatric toxicity tables. Draft November, 2007, 〈http://www.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/Documents/dmidpedtox.pdf〉 (accessed 29 May 2014).
29. National Children Study Terminology, 2014. available at: 〈http://evs.nci.nih.gov/ftp1/nichd/〉 (accessed July, 2014).
30. NICHD Maternal-fetal medicine units (MFMU) network 2014, Available at: 〈https://www.nichd.nih.gov/research/supported/Pages/mfmu.aspx〉 (accessed 29 May 2014).
31. Research Triangle Institute, NICHD Neonatal research network 2014, Available at: 〈https://neonatal.rti.org/about/network.cfm〉 (accessed 29 May 2014).
32. Global Alliance to Prevent Prematurity and Stillbirth (GAPPS) An initiative of Seattle Children's Hospital, Research and Foundation, 2014. Available at: 〈http://gapps.org/〉 (Accessed 02 June 2014).
33. GAVI Alliance GAVI's mission 2014, Available at: 〈http://www.gavialliance.org/about/mission/〉 (Accessed 02 June 2014).
34. UNICEF United States fund 2014, Available at: 〈http://www.unicefusa.org/〉 (accessed 02 June 2014).
35. World Health Organization (WHO) Health topics: maternal health 2014, Available at: 〈http://www.who.int/topics/maternal_health/en/〉 (accessed 02 June 2014).
36. Souza J.P., Gulmezoglu A.M., Vogel J., Carroli G., Lumbiganon P., Qureshi Z., et al. Moving beyond essential interventions for reduction of maternal mortality (the WHO Multicountry survey on maternal and newborn health): a cross sectional study. Lancet 2013, 381:1747-1755.
37. Kasenbaum N., Bertozzi-Villa A., Coggeshall M.S., et al. Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014, 2(May):1014. (epub).
38. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
39. Lawn J.E., Blencove H., Pattison R., Causens S., Kumar R., Ibiebele I., et al. Stillbirths: where? When? Why? How to make the data count?. Lancet 2011, 377:1448-1463.
40. Lawn J.E., Lee A.C.C., Kinney M., Sibley M., Carlo A.W., Paul V., et al. Two million intrapartum related stillbirths and neonatal deaths: where, why and what can be done?. Int J Gynecol Obstet 2009, 107:S5-S19.
41. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) published by the U.S. Public Health Service and Health Care Financing Administration, available at: 〈http://www.cms.gov/index.html〉.
42. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) published by the U.S. Public Health Service and Health Care Financing Administration, available at: 〈http://www.cms.gov/index.html〉.
43. US Department of Health and Human Services, National Institutes of Health and National Cancer Institute Common terminology criteria for adverse events (CTCAE). Version 4.0 2009, (Published May 28, 2009 (v4.03:June 14, 2010)).
44. Medical Dictionary for Regulatory Activities (MeDRA) Medical Dictionary for Regulatory Activities (MeDRA) of the international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH) 2015, Accessible at: 〈http://www.meddra.org/〉 (accessed July 24, 2015).
45. Eurocat Garne, Ester EUROCAT report: developing the surveillance of multiple congenital anomalies 2014.
46. EUROCAT. Coding of Anomalies. Available at: 〈www.eurocat-network.eu/newprevdata/appendices.cgi〉.
47. EUROCAT EUROCAT syndrome guide. Definition and coding of syndromes 2004, Available at: 〈www.eurocat.ulster.ac.uk〉 (revised 2008).
48. Loane M., Dolk H., Garne E., Greenlees R. Paper 3. EUROCAT data quality indicators for population based registries of congenital anomalies. Birth Defects Res (A) 2011, 91:S23-S30. EUROCAT Working Group.
49. Wellesley D, Boyd P, Dolk H, Pattenden S. An etiological classification of birth defects for epidemiological research. J Med Genet, Vol 42, No.1, pp 54-57. Available at: 〈http://www.eurocat.ulster.ac.uk/pubdata/〉.
50. Metropolitan Atlanta Congenital Defects Program (MACDP) Birth defects. Available from: 〈http://www.cdc.govncbddd/birthdefects/macdp.html〉.
51. National Birth Defects Prevention Network. Birth defects surveillance guidelines. Available at: 〈http://www.nbdpn.org/birth_defects_surveillance:gui.php〉.
52. International Birth Defects Information Systems. Website: 〈http://www.ibis-birthdefects.org/〉.
53. International Clearinghouse for Birth Defects Surveillance and Research. Website: 〈http://www.icbdsr.org〉.
54. World Health Organization (WHO), National Center on Birth Defects and Developmental Disabilities from the United States Centers for Disease Control and Prevention (CDC), International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) Birth defects surveillance: a manual for programme managers 2014, World Health Organization, Geneva, Available at: 〈http://www.who.int/nutrition/publications/birthdefects_manual/en/〉.
55. Rasmussen S.A., Olney R.S., Holmes L.B., et al. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res (A) 2003, 67:193-201.
56. Council for International Organizations of Medical Services (CIOMS), World Health Organization (WHO) Definition and application of terms for vaccine pharmacovigilance. Report of CIOMS/WHO working group on vaccine pharmacovigilance 2012, Available at: 〈http://whglibdoc.who.int/publications/2012/9789290360834_eng.pdf〉.
57. CDC Vaccine safety. Clinical immunization safety assessment (CISA) project 2014, Available at: 〈http://www.cdc.gov/vaccinesafety/activities/cisa.html〉 (accessed 29 May 2014).
58. The Vaccine Adverse Event Reporting System (VAERS), 2015. Available at: 〈https://vaers.hhs.gov/index〉, (accessed July 24, 2015).
59. Martin J.A., Hamilton B.E., Ventura J.S., Osterman M.J.K., Wilson A.C., Mathews T.J. Births: final data for 2010. National vital statistics reports of the Centers for Disease Control and Prevention August, 2012, vol. 61. The Division of Vital Statistics, (No. 1).
60. Hamilton B.E., Martin J.A., Osterman M.J.K., Curtin S.C. Births: preliminary data for 2013. National vital statistics report of the Centers for Disease Control and Prevention May, 2014, vol. 63. The Division of Vital Statistics, Available at: 〈http://www.cdc.gov/nchs/data/nvsr/nvsr63/〉 (No. 2).
61. American College of Obstetrics and Gynecology Practice bulletins 2014, Available at: 〈http://www.acog.org〉 (accessed 23 July, 2014).
62. American College of Obstetrics and Gynecology reVITALize definitions 2014, Available at: 〈http://www.ACOG.org〉, (accessed 23 July, 2014).
63. Brighton Collaboration Resources, 2015. Website available at: 〈http://brightoncollaboration.org/public/resources/standards/case-definitions/pregnancy.html〉 (accessed April 25, 2015).
64. GAIA Consortium Website, 2015, Available at: 〈http://gaia-consortium.net〉, (accessed May 30, 2015).
65. Maure C.G., Dodoo A.N., Bonhoeffer J., Zuber P.L.F. The global vaccine safety initiative: enhancing vaccine pharmacovigilance capacity at country level. Bull World Health Organ. 2014, 92(9):695-696.